Optimizing emetic control in children receiving antineoplastic therapy: Beyond the guidelines

被引：16

作者：

Lee Dupuis L. ^{[1
,2
,3
,4
]}

Nathan P.C. ^{[2
,3
,5
]}

机构：

[1] Clinical Pharmacy Specialist, Department of Pharmacy, Hospital for Sick Children, Toronto, ON M5G 1X8

[2] Division of HaematologyOncology, Hospital for Sick Children, Toronto, ON

[3] Research Institute, Hospital for Sick Children, Toronto, ON

[4] Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON

[5] Departments of Pediatrics and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON

来源：

Pediatric Drugs | 2010年 / 12卷 / 1期

关键词：

Acupressure; Acupuncture; Antiemetics; therapeutic use; Antineoplastics; Aprepitant; Chemotherapy-induced-nausea-and-; vomiting; treatment; Children; Corticosteroids; Dexamethasone;

D O I：

10.2165/11316190-000000000-00000

中图分类号：

学科分类号：

摘要：

Existing guidelines for the prevention of antineoplastic chemotherapy-induced nausea and vomiting (CINV) in children are constrained by the lack of robust evidence. Current guidelines recommend the use of a serotonin 5-HT3 receptor antagonist plus a corticosteroid to prevent acute CINV. Consequently, antiemetic agents that are recommended for use in adult cancer patients do not appear in the current pediatric guidelines. In addition, there is no information to guide the selection of alternative antiemetic agents for children who either cannot receive the recommended agents or who do not respond adequately to the treatment. Possible barriers to adherence to the pediatric antiemetic selection guidelines that are currently available are discussed, and published pediatric experience with antiemetic agents recommended in the current adult antiemetic selection guidelines (dolasetron, tropisetron, palonosetron, aprepitant) is summarized in this review. The use of novel and emerging antiemetic therapeutic interventions {metopimazine, diphenhydramine (Benadryl®)-lorazepam (Avitan®)-dexamethasone (Decadron®) BAD, nabilone, acupuncture, midazolam, olanzapine, mirtazapine, gabapentin, droperidol} in children are explored. © 2010 Adis Data Information BV. All rights reserved.

引用

页码：51 / 61

页数：10

共 97 条

[1]

Roila F., Feyer P., Maranzano R., Et al., Antiemetics in children receiving chemotherapy, Support Care Cancer, 13, pp. 129-131, (2005)

[2]

Kris M.G., Hesketh P.J., Somerfield M.R., Et al., American Society of Clinical Oncology guidelines for antiemetics in oncology: Update 2006, J Clin Oncol, 24, pp. 2932-2947, (2006)

[3]

Robson H., Meyer S., Shalet S., Et al., The anti-tumor effects of cytotoxics are modulated by glucocorticoids in human osteosarcoma in vitro [abstract], Med Pediatr Oncol, 33, (1999)

[4]

Weller M., Schmidt C., Roth W., Et al., Chemotherapy of human malignant glioma: Prevention of efficacy by dexamethasone?, Neurology, 48, pp. 1704-1709, (1997)

[5]

Rieger J., Durka S., Streffer J., Et al., Gemcitabine cytotoxicity of human malignant glioma cells: Modulation by antioxidants, BCL-2 and dexamethasone, Eur J Pharmacol, 365, pp. 301-308, (1999)

[6]

Mariotta M., Perewusnyk G., Koechli O.R., Et al., Dexamethasone-induced enhancement of resistance to ionizing radiation and chemotherapeutic agents in human tumor cells, Strahlenther Onkol, 175, pp. 392-396, (1999)

[7]

Straathof C.S., Van Den Bent M.J., Ma J., Et al., The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor, J Neurooncol, 37, pp. 1-8, (1998)

[8]

Vardy J., Chiew K.S., Galica J., Et al., Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy, Br J Cancer, 94, pp. 1011-1015, (2006)

[9]

Hochhauser C.J., Lewis M., Kamen B.A., Et al., Steroid-induced alterations of mood and behavior in children during treatment for acute lymphoblastic leukemia, Support Care Cancer, 13, pp. 967-974, (2005)

[10]

Bodey G.P., Fungal infections complicating acute leukemia, J Chronic Dis, 19, pp. 667-687, (1966)

← 1 2 3 4 5 6 7 8 9 10 →